17 Results for "

RDC peptide

" in MedChemExpress (MCE) Product Catalog:
Products (17)

17 Results for "RDC peptide" in MCE Product Catalog:

4
4 Cited Publications
Cat. No.: HY-106244
CAS No.: 177943-88-3
Purity:  99.95%
Synonyms: Oxodotreotide
Research Areas:  

Cancer

DOTATATE is a DOTA-conjugated peptide. DOTATATE can be labelled with radionuclides for positron emission tomography (PET) imaging and peptide receptor radionuclide research (PRRT) . DOTATATE can be used for the synthesis/research of Radionuclide-Drug Conjugates (RDCs).
loading...
    loading...
4
4 Cited Publications
Cat. No.: HY-106244A
CAS No.: 177943-89-4
Purity:  99.82%
Synonyms: Oxodotreotide acetate
Research Areas:  

Cancer

DOTATATE acetate is a DOTA-conjugated peptide. DOTATATE acetate can be labelled with radionuclides for positron emission tomography (PET) imaging and peptide receptor radionuclide research (PRRT) . DOTATATE (acetate) can be used for the synthesis/research of Radionuclide-Drug Conjugates (RDCs).
loading...
    loading...
2
2 Cited Publications
Cat. No.: HY-153549
CAS No.: 1341207-62-2
Purity:  99.03%
Research Areas:  

Others

Pentixafor is a peptide that targets CXCR4. Pentixafor is capable of being labelled with 68Gallium ( 68Ga) for positron emission tomography (PET) imaging . Pentixafor can be used for the synthesis/research of Radionuclide-Drug Conjugates (RDCs).
loading...
    loading...
Cat. No.: HY-P10761
CAS No.: 2941391-49-5
DPI-4452 is a CAIX-targeting cyclic peptide with a DOTA cage, and can be chelated with radionuclide for CAIX-expressing tumor PET-CT imaging and study. DPI-4452 specifically and selectively binds CAIX without interaction with an in vitro off-target receptor panel of 55 targets (IC50 for recombinant hCAIX: 130 nM). Radiolabeled DPI-4452 inhibits tumor growth in HT-29 and SK-RC-52 xenograft mouse models . DPI-4452 can be used for the synthesis/research of Radionuclide-Drug Conjugates (RDCs).
loading...
    loading...
Cat. No.: HY-W1124925
CAS No.: 3066439-94-6
DOTA-GPC3 targeting peptide 2 (Sequence 30) is a RDC peptide targeting GPC3, with Kd of 0.3 nM. DOTA-GPC3 targeting peptide 2 is composed of DOTA and GPC3 targeting peptide 2. DOTA-GPC3 targeting peptide 2 can be labeled with radioactive elements .
loading...
    loading...
Cat. No.: HY-P2218
CAS No.: 1821136-83-7
Research Areas:  

Cancer

Anditixafortide (Pentixather) is an endoradiotherapeutic vector. Anditixafortide is a CXCR4-targeting peptide derivative . Anditixafortide can be used for the synthesis/research of Radionuclide-Drug Conjugates (RDCs).
loading...
    loading...
Cat. No.: HY-P10741
CAS No.: 2151063-66-8
DOTA-EB-TATE is composed of SST peptide derivative, DOTA-octreotate conjugated a common to an Evans blue analog (EB). DOTA-EB-TATE is a peptide drug conjugate (PDC) improves the pharmacokinetics of SSTR2 analogs and reduces PRRT toxicity. DOTA-EB-TATE can also be used for the synthesis/research of Radionuclide-Drug Conjugates (RDCs) .
loading...
    loading...
Cat. No.: HY-P5297
Research Areas:  

Cancer

DOTA-CXCR4-L is a CXCR4 targeting peptide. DOTA-CXCR4-L can be used in the study of cancers, including glioblastoma and triple-negative breast cancer. NODAGA-LM3 can be labeled with [68Ga]/[177Lu] for the synthesis/research of Radionuclide-Drug Conjugates (RDCs) .
loading...
    loading...
Cat. No.: HY-P10444
CAS No.: 3033865-40-3
Research Areas:  

Cancer

DOTA Conjugated JM#21 derivative 7 (compound Ligand-7) is a derivative of CXCR4 targeting peptide conjugated with DOTA and can be used to produce radioligands. Radiolabeled DOTA Conjugated JM#21 derivative 7, i.e., 177Lu-DOTA, has excellent CXCR4 tumor targeting. In vitro biodistribution results of 177Lu-DOTA showed very low uptake in all non-targeted organs except kidney . DOTA Conjugated JM#21 derivative 7 can be used for the synthesis/research of Radionuclide-Drug Conjugates (RDCs).
loading...
    loading...
Cat. No.: HY-P10945B
Research Areas:  

Cancer

Cys-FAP targeting peptide for FXX489 TFA is the polypeptide part of Unlabeled FXX489 (HY-P10944). Unlabeled FXX489 is a fibroblast activation protein (FAP)-targeting ligand .
loading...
    loading...
Cat. No.: HY-P10307
Research Areas:  

Infection

DOTA-ubiquicidin (29-41), an antimicrobial peptide fragment derivative, can be used for synthesis of [ 68Ga]Ga-DOTA-Ubiquicidin29-41 and then used for imaging of infectious processes using PET/CT . DOTA-ubiquicidin (29–41) can be used for the synthesis/research of Radionuclide-Drug Conjugates (RDCs).
loading...
    loading...
Cat. No.: HY-P10945A
Research Areas:  

Cancer

Cys-FAP targeting peptide for FXX489 is the polypeptide part of Unlabeled FXX489 (HY-P10944). Unlabeled FXX489 is a fibroblast activation protein (FAP)-targeting ligand .
loading...
    loading...
Cat. No.: HY-W738256A
Synonyms: MDTPA TFA
Research Areas:  

Cancer

Maleimide-DTPA (MDTPA) TFA is a monoreactive DTPA derivative (MDTPA) with maleimide group as peptide binding site, which can be combined with radionuclides to prepare radionuclide conjugates (RDC). Maleimide-DTPA TFA can chelate indium-111 (111In) and label peptides and peptides with indium-111. For example, it has high stability when combined with OST7 incubated in human serum, which is better than cyclic cDTPA. Maleimide-DTPA TFA is a good material for medical imaging or treatment .
loading...
    loading...
Cat. No.: HY-P81524
Synonyms: vasoactive inTinal peptide receptor 1; II; HVR1; RDC1; V1RG; VIPR; VIRG; VAPC1; VPAC1; VPAC1R; VIP-R-1; VPCAP1R; PACAP-R2; PACAP-R-2

Host:  

Rabbit

Application:  

IHC-P

Reactivity:  

Human

loading...
    loading...
Cat. No.: HY-P81524A
Synonyms: vasoactive inTinal peptide receptor 1; II; HVR1; RDC1; V1RG; VIPR; VIRG; VAPC1; VPAC1; VPAC1R; VIP-R-1; VPCAP1R; PACAP-R2; PACAP-R-2

Host:  

Rabbit

Application:  

IHC-P

Reactivity:  

Human

loading...
    loading...
Cat. No.: HY-P11485
JR11-PEG3-HBED-CC-PSMA-03 (Compound 1) is an RDC-related compound containing the chelating agent HBED-CC, the JR11 peptide (SSTR2 antagonist), and the PSMA ligand. JR11-PEG3-HBED-CC-PSMA-03 shows SSTR2-binding affinities and PSMA-binding affinities, with IC50 s of 59.2 nM, 57.0 nM, respectively. JR11-PEG3-HBED-CC-PSMA-03 can be radiolabeled with [ 68Ga]. [ 68Ga] radiolabeled JR11-PEG3-HBED-CC-PSMA-03 can be used in diagnostic studies of neuroendocrine differentiated prostate cancer .
loading...
    loading...
Cat. No.: HY-P11488
JR11-PEG3-DOTA-PSMA-03 (Compound 2) is an RDC-related compound containing the chelating agent DOTA (HY-W053583), the JR11 peptide (SSTR2 antagonist), and the PSMA ligand. JR11-PEG3-DOTA-PSMA-03 shows SSTR2-binding affinities and PSMA-binding affinities, with IC50 s of 94.0 nM, 81.8 nM, respectively. JR11-PEG3-DOTA-PSMA-03 can be radiolabeled with [ 68Ga]. [ 68Ga] radiolabeled JR11-PEG3-DOTA-PSMA-03 can be used in diagnostic studies of neuroendocrine differentiated prostate cancer .
loading...
    loading...
  • 1